



## Bodisen Biotech, Inc. Financials

PERIOD ENDING	30-Sep-04	30-Jun-04	31-Mar-04	31-Dec-03
<b>Total Revenue</b>	<b>5,408</b>	<b>4,230</b>	<b>2,186</b>	<b>5</b>
Cost of Revenue	3,389	2,243	1,313	-
<b>Gross Profit</b>	<b>2,019</b>	<b>1,987</b>	<b>873</b>	<b>5</b>
<b>Operating Expenses</b>				
Research Development	-	-	-	-
Selling General and Administrative	406	234	350	21
Non Recurring	-	-	-	-
Others	-	-	-	1
Total Operating Expenses	-	-	-	-
<b>Operating Income or Loss</b>	<b>1,613</b>	<b>1,753</b>	<b>523</b>	<b>(17)</b>
<b>Income from Continuing Operations</b>				
Total Other Income/Expenses Net	4	8	-	0
Earnings Before Interest And Taxes	1,617	1,761	523	(16)
Interest Expense	20	11	27	-
Income Before Tax	1,597	1,750	495	(16)
Income Tax Expense	-	(74)	74	-
Minority Interest	-	-	-	-
Net Income From Continuing Ops	1,597	1,824	421	(16)
<b>Non-recurring Events</b>				
Discontinued Operations	-	-	-	-
Extraordinary Items	-	-	-	-
Effect Of Accounting Changes	-	-	-	-
Other Items	-	-	-	-
<b>Net Income</b>	<b>1,597</b>	<b>1,824</b>	<b>421</b>	<b>(16)</b>
Preferred Stock And Other Adjustments	-	-	-	-
<b>Net Income Applicable To Common Shares</b>	<b>\$1,597</b>	<b>\$1,824</b>	<b>\$421</b>	<b>(\$16)</b>